Deep vein thrombosis during vaccination against SARS-CoV-2 period

Abstract

Objectives: since the beginning of vaccination against SARS-CoV-2 virus one of the most frequent entities of venous thromboembolism (VTE), deep vein thrombosis (DVT), has been scarcely documented. We analyze DVT episodes during vaccination against SARS-CoV-2 period. Material and methods: retrospective unicenter analysis including patients diagnosed with DVT (January -September 2021). Patients were divided into two groups, vaccinated and unvaccinated against SARS-CoV-2 28 days prior to DVT symptoms onset. Primary endpoint: DVT severity (pulmonary embolism (PE) and/or hospital admission). Secondary endpoints: DVT risk factors (unprovoked, VTE antecedent, immobilization, trauma, surgery, thrombophilia, hormone therapy and cancer). Results: there were 192 DVT diagnoses, 42 (21, 9 %) vaccinated and 150 (78, 1 %) unvaccinated. DVT severity: PE: 52, 4 % vaccinated vs. 62, 7 % controls (p = 0, 228); hospital admission: 52, 4 % vaccinated vs. 62, 4 % unvaccinated (p = 0, 536); unprovoked DVT: 28, 6 % vaccinated vs. 48 % unvaccinated (p = 0, 025); VTE antecedent: 21, 4 % vaccinated vs. 17, 3 % unvaccinated (p = 0, 543): immobilization: 7, 1 % vaccinated vs. 12, 7 % unvaccinated; trauma: 4, 8 % vaccinated vs. 6 % unvaccinated (p = 1); surgery: 4, 8 % vaccinated vs. 1, 3 % unvaccinated (p = 0, 209); thrombophilia: 16, 7 % vaccinated vs. 4 % unvaccinaed (p = 0, 009); hormone theraphy: 9, 5 % vaccinated vs. 3, 3 % unvaccinated (p = 0, 107); cancer: 28, 6 % vaccinated vs. 18, 7 % unvaccinated (p = 0, 162). Multivariate analysis showed a higher risk of DVT in vaccinated patients with thrombophilia, with an OR of 6, 10 (95 % CI, 1, 52-24, 37). Conclusion: vaccination against SARS-CoV-2 doesn't seem to increased DVT severity, although a higher incidence of DVT in vaccinated patients with thrombophilia was observed.